Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jul 21, 2009

Premium

Direct-to-consumer genetic testing startup Pathways Genomics of San Diego last week announced its executive team.

Jim Plante is the company's founder and CEO. Previously, he founded four technology companies and launched products and services in the consumer products, automotive, wireless, and risk-management industries. Plante holds a BS in electrical engineering from Southern Illinois University.

David Becker is Pathway Genomics' CSO. Previously, he did research at Torrey Pines Therapeutics, formerly Neurogenetics, where he focused on genes that contribute to the pathogenesis of Alzheimer's disease. Prior to that, he worked as a scientist at Mitokor. Becker holds a PhD in biology from San Diego State University and the University of California, San Diego, and an undergraduate degree from the University of California, Santa Barbara.

Michael Nova is the company's chief medical officer. He is a physician at Pacific dermatopathology labs and the CEO and founder of HuTrube, a mobile social-location company. He also founded Graviton, a wireless sensory network company. In addition, he is the founder and former CEO of Discovery Partners, which markets wireless drug discovery technology and radiofrequency combinatorial chemistry to large pharma companies. Nova holds degrees in biochemistry, physics, and medicine from the University of California, Berkeley and Albert Einstein College of Medicine.

Rudolph Tanzi and John Reed are scientific advisors of Pathway Genomics. Tanzi is the director of the genetics and aging research unit at the MassGeneral Institute for Neurodegenerative Diseases at Massachusetts General Hospital, and a professor of neurology at Harvard Medical School.

Reed is the president and CEO of the Burnham Institute for Medical Research, and a professor and chair at the institute.


Chronix Biomedical has appointed Paul Freiman as chairman of its board of directors. Most recently, he was president and CEO of Neurobiological Technologies. He is also the former chairman and CEO of Syntex. Freiman holds a BS from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.